Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26461707 |
US |
84 | 2 |
Accidental exposure to product, Device deployment issue, Exposure via skin contact, |
||||
ABATACEPT, |
||||
| 302 | 26463955 |
US |
74 | 2 |
Coronary artery occlusion, Blood viscosity decreased, Haemorrhage, Contusion, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
EVOLOCUMAB, ROSUVASTATIN, CLOPIDOGREL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 303 | 26464006 |
US |
59 | 2 |
Exposure via skin contact, Accidental exposure to product, Injection site pain, Injection site pruritus, Lack of injection site rotation, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 304 | 26464024 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 305 | 26464028 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 306 | 26458131 |
US |
||
Device leakage, Exposure via skin contact, No adverse event, |
||||
FARICIMAB, FARICIMAB, FARICIMAB, FARICIMAB, |
||||
| 307 | 26458426 |
US |
67 | 2 |
Asthma, Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, DUPILUMAB, |
||||
| 308 | 26454002 |
US |
67 | 2 |
Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 309 | 26455108 |
US |
78 | 1 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 310 | 26455455 |
US |
41 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 311 | 26455739 |
US |
1 | |
Accidental exposure to product, Device malfunction, Device delivery system issue, Drug dose omission by device, Exposure via skin contact, |
||||
SECUKINUMAB, |
||||
| 312 | 26455796 |
US |
||
Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 313 | 26455941 |
US |
1 | |
Device leakage, Device issue, Device delivery system issue, Exposure via skin contact, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 314 | 26456150 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, Wrong technique in device usage process, |
||||
SECUKINUMAB, |
||||
| 315 | 26456620 |
US |
87 | 2 |
Incorrect dose administered by device, Device use error, Product communication issue, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 316 | 26456624 |
US |
67 | 1 |
Accidental exposure to product, Product administration error, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 317 | 26456676 |
US |
63 | 2 |
Injection site mass, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 318 | 26448679 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-ATTO, |
||||
| 319 | 26448861 |
US |
1 | |
Drug ineffective, Product delivery mechanism issue, Accidental exposure to product, Exposure via skin contact, |
||||
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, |
||||
| 320 | 26450310 |
US |
74 | 2 |
Exposure via skin contact, Device malfunction, Device leakage, Incorrect dose administered, No adverse event, |
||||
OMALIZUMAB, |
||||
| 321 | 26450532 |
US |
1 | |
Vision blurred, Exposure via skin contact, Accidental exposure to product, Product use complaint, Product delivery mechanism issue, Product container issue, |
||||
LIFITEGRAST, LIFITEGRAST, |
||||
| 322 | 26452375 |
US |
2 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
SECUKINUMAB, |
||||
| 323 | 26452661 |
US |
41 | 1 |
Product communication issue, Wrong technique in product usage process, Device difficult to use, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 324 | 26446052 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 325 | 26446064 |
US |
82 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 326 | 26446083 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 327 | 26446113 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 328 | 26446262 |
US |
62 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 329 | 26446418 |
US |
35 | 2 |
Product dispensing error, Maternal exposure during pregnancy, Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, |
||||
| 330 | 26446434 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, LINACLOTIDE, LOSARTAN POTASSIUM, LOSARTAN, ROSUVASTATIN CALCIUM, ERGOCALCIFEROL, GABAPENTIN, METHYLPREDNISOLONE, AZITHROMYCIN DIHYDRATE, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BUDESONIDE, FLUTICASONE PROPIONATE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, MEPOLIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, PREDNISONE, IPRATROPIUM BROMIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, OXYBUTYNIN CHLORIDE, MONTELUKAST SODIUM, MONTELUKAST, NIFEDIPINE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ROFLUMILAST, EZETIMIBE, |
||||
| 331 | 26446456 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 332 | 26446551 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 333 | 26446594 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 334 | 26446602 |
US |
||
Accidental exposure to product, Exposure via skin contact, Device delivery system issue, |
||||
GUSELKUMAB, |
||||
| 335 | 26446644 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 336 | 26446737 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 337 | 26446752 |
US |
1 | |
Dyspnoea, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, METHYLPREDNISOLONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, EZETIMIBE, MELOXICAM, ATOGEPANT, RANOLAZINE, ROSUVASTATIN, ERGOCALCIFEROL, |
||||
| 338 | 26446873 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 339 | 26446918 |
US |
68 | 1 |
Glycosylated haemoglobin decreased, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 340 | 26446923 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 341 | 26446990 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 342 | 26447037 |
US |
62 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 343 | 26447045 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 344 | 26447063 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 345 | 26447178 |
US |
33 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 346 | 26447188 |
US |
80 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 347 | 26447338 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 348 | 26447381 |
US |
26 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 349 | 26447382 |
US |
2 | |
Injection site mass, Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 350 | 26447424 |
US |
2 | |
Injection site swelling, Device defective, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 351 | 26447451 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 352 | 26447482 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 353 | 26447497 |
US |
82 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 354 | 26447554 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 355 | 26447665 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, Eczema, Postural orthostatic tachycardia syndrome, Rash, Skin discolouration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 356 | 26447677 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 357 | 26447715 |
US |
56 | 2 |
Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 358 | 26447792 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 359 | 26447807 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 360 | 26447915 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 361 | 26448024 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 362 | 26441375 |
US |
31 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Device malfunction, Incorrect dose administered by device, |
||||
ABATACEPT, DULOXETINE HYDROCHLORIDE, DULOXETINE, ETODOLAC, GABAPENTIN, ETONOGESTREL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PANTOPRAZOLE, PREDNISONE, ERGOCALCIFEROL, |
||||
| 363 | 26441860 |
US |
78 | 2 |
Rash pruritic, Ocular hyperaemia, Exposure via skin contact, Accidental exposure to product, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 364 | 26442086 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 365 | 26442347 |
US |
34 | 2 |
Wrong technique in product usage process, Exposure via skin contact, Device use error, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 366 | 26442579 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN LISPRO, |
||||
| 367 | 26442762 |
US |
76 | 2 |
Injection site haemorrhage, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 368 | 26442770 |
US |
2 | |
Exposure via skin contact, Device leakage, Device issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 369 | 26443458 |
US |
70 | 1 |
Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 370 | 26444335 |
US |
84 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 371 | 26444338 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 372 | 26444387 |
US |
38 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 373 | 26444390 |
US |
77 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 374 | 26444435 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 375 | 26444464 |
US |
3 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 376 | 26444480 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 377 | 26444508 |
US |
1 | |
Injection site vesicles, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 378 | 26444629 |
US |
70 | 2 |
Incorrect disposal of product, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, Wrong technique in product usage process, Injection site haemorrhage, Injection site pain, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 379 | 26445222 |
US |
68 | 2 |
Pneumonia, Upper respiratory tract infection, Cough, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ATENOLOL, BUPROPION, ERGOCALCIFEROL, GABAPENTIN, LISINOPRIL, |
||||
| 380 | 26445309 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 381 | 26445330 |
US |
84 | 2 |
Incorrect dose administered by device, Contusion, Injection site haemorrhage, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, |
||||
ABATACEPT, AMLODIPINE, |
||||
| 382 | 26445381 |
US |
70 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 383 | 26436478 |
US |
89 | 2 |
Herpes zoster, Exposure via skin contact, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 384 | 26436579 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 385 | 26437021 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, Product administration error, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 386 | 26437090 |
US |
2 | |
Exposure via skin contact, |
||||
ADALIMUMAB-ATTO, ADALIMUMAB-ATTO, |
||||
| 387 | 26437399 |
CA |
58 | 2 |
Accidental exposure to product, Condition aggravated, Device malfunction, Exposure via skin contact, Intentional dose omission, Lower respiratory tract infection, Product availability issue, Product label issue, Therapy interrupted, Unevaluable event, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ALBUTEROL SULFATE, ALBUTEROL, FUROSEMIDE, HYDROXYCHLOROQUINE, MELOXICAM, PANTOPRAZOLE, PREGABALIN, ROSUVASTATIN CALCIUM, TEMAZEPAM, |
||||
| 388 | 26437507 |
US |
61 | 1 |
Accidental exposure to product, Device difficult to use, Exposure via skin contact, |
||||
ADALIMUMAB-ATTO, |
||||
| 389 | 26437567 |
US |
70 | 2 |
Device issue, Accidental exposure to product, Exposure via skin contact, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 390 | 26437878 |
US |
57 | 1 |
Device delivery system issue, Accidental exposure to product, Incorrect dose administered by device, Exposure via skin contact, Injection site haemorrhage, |
||||
ABATACEPT, AZATHIOPRINE, LOSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 391 | 26438943 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 392 | 26438955 |
US |
70 | 1 |
Neuropathy peripheral, Muscle spasms, Hypoaesthesia, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 393 | 26438964 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 394 | 26438969 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN LISPRO, |
||||
| 395 | 26438983 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 396 | 26438984 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 397 | 26438988 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 398 | 26439096 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 399 | 26439110 |
US |
47 | 2 |
Contusion, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FAMOTIDINE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, IRBESARTAN, ESCITALOPRAM OXALATE, ESCITALOPRAM, PRAVASTATIN SODIUM, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LISDEXAMFETAMINE DIMESYLATE, MONTELUKAST SODIUM, MONTELUKAST, ALPRAZOLAM, PANTOPRAZOLE SODIUM, |
||||
| 400 | 26439124 |
US |
75 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Incorrect route of product administration, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28